Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Circulating tumor cells (CTCs) in blood are accepted as a prognostic marker for patients with metastatic colorectal cancer (CRC). However, there is limited data on the use of CTCs as a prognostic marker for non-metastatic patients. In the current study, we used a rare cell automated analysis platform, the MiSelect R System, to enumerate CTCs from blood in non-metastatic CRC patients, and corelated the number of CTCs with the clinical staging and survival. The presence of CTCs in mesenteric vein blood (MVB) samples from 101 CRC patients was significantly associated with T stage. Patients with 1 or more CTCs per 8 mL of MVB exhibited significantly worse disease-free survival (DFS) and cancer-specific survival (CSS) compared to patient without CTCs. The presence of CTCs before surgery is an independent marker for both DFS and CSS. CTC presence after surgical resection is also a prognostic marker. CTCs are a potentially useful prognostic and predictive biomarker in non-metastatic CRC patients that may further stratify patient's risk status within different stages of disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036555 | PMC |
| http://dx.doi.org/10.1038/s41598-023-31346-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Gut microbiota dysbiosis in people living with HIV who have cancer: novel insights and diagnostic potential.
Front Immunol
September 2025
Guangxi Key Laboratory of AIDS Prevention and Treatment & School of Public Health, Guangxi Medical University, Nanning, Guangxi, China.
Background: People living with HIV(PLWH) are a high-risk population for cancer. We conducted a pioneering study on the gut microbiota of PLWH with various types of cancer, revealing key microbiota.
Methods: We collected stool samples from 54 PLWH who have cancer (PLWH-C), including Kaposi's sarcoma (KS, n=7), lymphoma (L, n=22), lung cancer (LC, n=12), and colorectal cancer (CRC, n=13), 55 PLWH who do not have cancer (PLWH-NC), and 49 people living without HIV (Ctrl).
Utilizing tumor deposit count as a stratification criterion in revising TNM staging system for patients with colorectal cancer: a nomogram review study.
Front Oncol
August 2025
Department of Surgery, Hebei Medical University, Shijiazhuang, Hebei, China.
Background: Tumor deposit (TD) is an independent risk factor associated with recurrence or metastasis for patients with colorectal cancer (CRC). The scenario in which both TD and lymph node metastasis (LNM) are positive is not clearly illustrated by the current TNM staging system. Simply treating one TD as one or two LNMs by a weighting factor is inappropriate.
View Article and Find Full Text PDFA compilation of 13 patients with metastatic colorectal cancer and concomitant and family mutations.
Front Oncol
August 2025
Department of Hematology and Oncology, Wake Forest University School of Medicine, Winston-Salem, NC, United States.
Introduction: Metastatic colorectal cancer (mCRC) exhibits significant heterogeneity in molecular profiles, influencing treatment response and patient outcomes. Mutations in v-raf murine sarcoma viral oncogene homolog B1 () and rat sarcoma () family genes are commonly observed in mCRC. Though originally thought to be mutually exclusive, recent data have shown that patients may present with concomitant and mutations, posing unique challenges and implications for clinical management.
View Article and Find Full Text PDFApproaches to address common barriers to colorectal cancer screening in rural communities of the CDC's colorectal cancer control program.
Prev Oncol Epidemiol
May 2025
Implenomics, Dover, DE, USA.
Introduction: We identified potential approaches to address barriers to colorectal cancer (CRC) screening in rural communities of award recipients from the Centers for Disease Control and Prevention's Colorectal Cancer Control Program (CRCCP).
Methods: Nine program managers and directors discussed approaches to address barriers to CRC screening. The programs served areas with rural communities and tribal reservations.
Complete Response to BET Inhibitor in Primary Pulmonary NUT Carcinoma With Single-Cell Sequencing-Based Analysis: A Case Report.
JTO Clin Res Rep
October 2025
Clinical Research Center (CRC), Medical Pathology Center (MPC), Cancer Early Detection and Treatment Center (CEDTC), and Translational Medicine Research Center (TMRC), Chongqing University Three Gorges Hospital, Wanzhou District, Chongqing, People's Republic of China.
NUT carcinoma is a rare and highly aggressive malignancy characterized by rapid progression, resistance to conventional therapies, and an extremely poor prognosis. This report presents a 36-year-old patient with stage IIIB primary pulmonary NUT carcinoma who achieved remarkable clinical outcomes with NHWD-870 monotherapy, a novel BET inhibitor. After just 1 month of treatment, imaging revealed a partial response, and a complete response was achieved within 5 months.
View Article and Find Full Text PDF